Siegfried to Acquire Early-Phase CDMO in Wisconsin to Boost Drug Substances Offering

Siegfried AG, a global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, has announced the acquisition of an early-phase CDMO site in Grafton, Wisconsin, from Curia Global. This move aims to enhance Siegfried's capabilities and geographic reach in Drug Substances services.

The new facility will be developed into Siegfried's North American Acceleration Hub for early-phase CDMO services, providing significant growth opportunities. The site employs over 80 experienced professionals and will contribute to Siegfried's global customer base, including projects involving highly potent APIs.

Reto Suter, CEO ad interim and CFO of Siegfried, stated that this acquisition will enhance their offering with early-stage development services, becoming more relevant to their customers. The acquisition underscores Siegfried's commitment to providing comprehensive support in pre-clinical and clinical development and manufacturing of Drug Substances, particularly for small and mid-sized pharmaceutical companies.

The transaction is expected to close by July 1, 2024, subject to customary closing conditions, and will be financed from existing funds. Importantly, Siegfried’s outlook for 2024 and mid-term financial targets remain unchanged.